Keywords: Bebign prostatic hyperplasia, Market forecasts, Generic erosion, Decision Resources

Generic erosion will reduce BPH/male urinary tract drug market to $4 billion in 2010

Article | 20 November 2011

The market for therapies that treat benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms will fluctuate over the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in